Safe ER/LA Opioid Prescribing

Introduction

In response to the steady increase of prescription opioid misuse, the FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Extended Release/Long Acting (ER/LA) opioid analgesics.  Physician and other clinician education is an important part of this strategy.  Below are resources and CME activities intended to reinforce proper prescribing practices and improve clinicians' recognition of opioid abuse signs.  While ER/LA opioid prescriptions are not common in the practice of ophthalmology, members are encouraged to stay current in all public health issues and to support physicians in other specialties.

Resources on ER/LA Opioids and REMS

• FDA: REMS Information for ER/LA Opioids and Blueprint for Prescriber Education
• FDA: Approved Risk Evaluation and Mitigation Strategies 
• National Institute on Drug Abuse: Prescription Drug Abuse
• Office of National Drug Control Policy: Fact Sheet on Prescription Drug Abuse and Heroin Use
• Information from REMS Program Companies

CME Activities

• ACCME's CME Finder
  
• CORE: Collaborative for REMS Education
  
• List of activities fulfilling REMS requirements, funded by REMS Program Companies
• Boston University School of Medicine: Chronic Pain